Yanuki
Health / Pharmaceuticals
Online telehealth company Hims & Hers is set to launch a copy of the Wegovy pill for $49, significantly undercutting Novo Nordisk’s $149 branded version. This announcement has sent shockwaves through the pharmaceutical market, impacting the...
Finance / Stocks
Eli Lilly (LLY) faces a setback in the weight loss drug market as its oral GLP-1 candidate, orforglipron, experiences FDA review delays. This article examines the implications and explores alternative investment opportunities in the pharmac...
Business / Pharmaceuticals
Eli Lilly is expanding its U.S. manufacturing footprint with a significant $6 billion investment in a new facility in Huntsville, Alabama. This move aims to boost domestic medicine production and strengthen supply chain resilience.
Health / Weight Loss
Eli Lilly has announced a reduction in the cash prices of its Zepbound (tirzepatide) single-dose vials, available through its direct-to-consumer platform, LillyDirect. This move aims to improve access to the weight loss drug for individuals...
Business / Health Science
Eli Lilly has achieved a $1 trillion market capitalization, marking the first time a healthcare company has reached this valuation, previously dominated by tech firms. This milestone is driven by the surging demand for its weight loss injec...
Finance / Stocks
Eli Lilly's tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, has become the world's top-selling drug, surpassing Merck's Keytruda. This reflects the increasing demand for GLP-1 drugs and Eli Lilly's strong market pos...
Finance / Pharmaceuticals
This article provides a recap of recent activity surrounding Eli Lilly & Company (LLY), including changes in institutional holdings, insider trading behaviors, analyst ratings, and price targets. It summarizes key movements and insights for...
Finance / Stock News
Apple (AAPL) and Eli Lilly (LLY) have experienced volatility but are now rebounding, presenting potential opportunities for growth and income investors. This article examines the factors driving their resurgence.
Health / Weight Loss
Eli Lilly's investigational oral GLP-1 receptor agonist, orforglipron, has demonstrated compelling efficacy in Phase 3 trials for weight loss and A1C reduction in adults with obesity or overweight and type 2 diabetes. These results pave the...
Health / Weight Loss
Eli Lilly's investigational oral pill, orforglipron, is showing promising results in late-stage trials for obesity treatment, paving the way for a potential new option in the weight loss market. This development is particularly significant...
Finance / Stocks
Eli Lilly and Company (NYSE:LLY) has garnered attention in the stock market, with Wall Street analysts offering varied perspectives on its potential. Recent reports highlight both optimistic upgrades and cautionary downgrades, reflecting th...
Business / Pharmaceuticals
Eli Lilly (LLY) is witnessing robust demand for its diabetes and weight-loss drug, Mounjaro, in India, driven by increasing rates of obesity and diabetes. The company is focused on meeting this rising demand, positioning Mounjaro as a key p...
Health / Weight Loss
Recent findings from a head-to-head trial have shed light on the effectiveness of two popular weight-loss drugs: Mounjaro (Tirzepatide) and Wegovy (Semaglutide). The study, published in the New England Journal of Medicine, directly compares...
Finance / Healthcare
The healthcare sector is facing a confluence of challenges, including potential tariffs on pharmaceuticals, increasing regulatory scrutiny, and evolving financial strategies. These factors are creating uncertainty and volatility in the mark...
Finance / Pharmaceuticals
Eli Lilly (LLY) reported first-quarter 2025 earnings that exceeded expectations, driven by strong sales of its weight loss drug Zepbound and diabetes treatment Mounjaro. However, the pharmaceutical giant lowered its full-year profit outlook...
